Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

15 Jul 2008

Abstract excerpt

PURPOSE: Histone deacetylase inhibitors can alter gene expression and mediate diverse antitumor activities. Herein, we report the safety and activity of the histone deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma (CTCL) and identify genes commonly regulated by panobinostat. EXPERIMENTAL DESIGN: Panobinostat was administered orally to patients with CTCL on Monday, Wednesday, and Friday of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cutaneous lymphoproliferative disorders research
Share to Histone Deacetylase Inhibitors Research
Share to T-cell and Retrovirus Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18628465
DOI: 10.1158/1078-0432.ccr-07-4262

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell LymphomaPMID 18628465Read ↗

Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer CellsSemantic proximity Read ↗

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applicationsSemantic proximity Read ↗

Histone Deacetylase Inhibitors for Peripheral T-cell Lymphomas: From Biology to Real-World TherapySemantic proximity Read ↗

Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell LymphomaSemantic proximity Read ↗

Lessons learned from gene expression profiling of cutaneous T-cell lymphomaSemantic proximity Read ↗

SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosisSemantic proximity Read ↗

Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphomaSemantic proximity Read ↗

Epigenetic Modulation with Histone Deacetylase Inhibitors in Combination with ImmunotherapySemantic proximity Read ↗

Histone Deacetylase Inhibitors: Emerging Mechanisms of ResistanceSemantic proximity Read ↗

Targeting HDACs for diffuse large B-cell lymphoma therapySemantic proximity Read ↗

Role of Histone Deacetylases in Drug-Resistant Melanoma: Mechanisms and Therapeutic ImplicationsSemantic proximity Read ↗

Targeting histone deacetylases in T-cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.